PierianDx Acquires Tute Genomics
Company Extends Ability to Deliver a Unified Sample-to-Report Software Platform for Clinical Labs
PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced today the acquisition of Tute Genomics, a genomics software company based in Provo, UT.
The acquisition furthers PierianDx’s goal to be the most comprehensive, integrated platform to enable personalized medicine for clinical labs. PierianDx’s Clinical Genomicist Workspace (CGW), one of the leading cloud-based software platforms for somatic cancer, will be enhanced through the addition of Tute Genomics’ leading constitutional and exome testing capabilities. The integrated offering will provide a single clinical platform for best in class clinical workflow support of somatic cancer and constitutional testing.
“We are excited to welcome Tute Genomics customers and employees to the PierianDx team,” said PierianDx CEO Ted Briscoe. “The enhanced platform will provide labs with a single clinical solution to support a comprehensive range of molecular testing for personalized medicine.”
As part of the transaction, Reid Robison, CEO of Tute, will join the PierianDx Board of Directors and Tute COO Andy Olson and Vice President of Product Development Bryce Daines will immediately relocate to St. Louis. PierianDx will maintain a development team in Provo, Utah.
“PierianDx is a leader in enabling precision medicine and I am confident that this partnership will significantly accelerate our shared vision of bringing genomics and personalized medicine into everyday healthcare,” said Robison.
Representatives from Healthbox, an investor in Tute and an innovation partner of Intermountain Healthcare, praised the acquisition.
“This type of consolidation is exactly what the industry needs to bring to market the most unified workflow solution for genomic testing,” said Healthbox Vice President Jeffrey Ries.
Founded in 2012, Tute Genomics has grown to become an industry-leading bioinformatics software platform. The company was co-founded by Dr. Kai Wang, a renowned computational biologist and inventor of ANNOVAR software, and Dr. Reid Robison, a physician, geneticist and entrepreneur. In December of 2015, Tute Genomics acquired the assets of Knome, a pioneer in human-genome interpretation, co-founded by geneticist and Harvard professor George Church.
PierianDx will maintain the Tute Genomics solution until the platforms are fully integrated into CGW 6.0 in the spring of 2017.
Learn more by clicking here.
PierianDx enables health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. In use since 2011, and regularly enhanced with new patient, clinical and research data, PierianDx’s proprietary Clinical Genomicist Workspace (CGW) provides clinical labs more streamlined and accurate analysis, interpretation, and reporting needed to accelerate their personalized medicine programs. PierianDx also recently launched the NGS Gateway Program, a CAP-accredited, CLIA-certified lab that complements PierianDx partners’ in-house NGS testing services. Clinical Genomicist Workspace™ is a trademark of PierianDx, Inc.